Novo Nordisk Queues Up $830M Suit Over Disappointing Drug

By Caroline Simson · February 18, 2025, 9:02 PM EST

Novo Nordisk is set to initiate an $830 million arbitration claim in New York accusing Singaporean biopharmaceutical company KBP Biosciences of misleading the Danish drugmaker about the potential of a new...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Decision

Recent Articles By Caroline

February 19, 2025
Walgreens Says $1B COVID Testing Award Must Be Nixed
February 14, 2025
CVS Wins Arbitration In Medicare Fee Antitrust Suit
January 03, 2025
Enforcement Of $146M Chilean Hospital Award Sought In Conn.
December 11, 2024
AADI Enlists NY Court To Enforce Cancer Drug Award
November 15, 2024
Ariz. Judge Will Decide Proper Venue For CVS Antitrust Suit
October 25, 2024
DC Circ. Could Nix OK Of $8M Equatorial Guinea Award
October 24, 2024
2nd Circ. Says Healthcare Arbitrations Were Properly Halted
October 09, 2024
$140M Chilean Hospital Award Fight Is Paused In Canada
September 30, 2024
Webuild Escapes Suit Over $140M Award In Delaware
July 10, 2024
Meijer Says Takeda Can't Force Antitrust Suit Into Arbitration